Keyphrases
Immune Thrombocytopenia
100%
Pediatric Patients
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Therapy Effect
100%
Late Effects
100%
Response to Therapy
100%
Patient Response
100%
Rituximab
25%
Day Range
25%
Graft-versus-host Disease (GvHD)
12%
Pediatric
12%
Intravenous Immunoglobulin (IVIg)
12%
First-line Therapy
12%
Treatment Outcome
12%
Corticosteroids
12%
Outcome Effect
12%
Treatment Effect
12%
Autoimmune Hemolytic Anemia
12%
Iron Overload
12%
Direct Therapy
12%
Human Leukocyte Antigen
12%
Daratumumab
12%
Overall Survival
12%
Conditioning Regimen
12%
Serious Complications
12%
Median Time
12%
Avascular Necrosis
12%
ABO Incompatibility
12%
Stem Cell Source
12%
Donor Engraftment
12%
Graft-versus-host Disease Prophylaxis
12%
Hypogammaglobulinemia
12%
Serotherapy
12%
B-cell Aplasia
12%
Immunology and Microbiology
Rituximab
100%
Hematopoietic Stem Cell Transplantation
100%
Graft-Versus-Host Disease
50%
Engraftment
50%
B Cell
50%
Cell Transplantation
50%
Intravenous Immunoglobulin
50%
Stem Cell
50%
Chronic Graft Versus Host Disease
50%
Daratumumab
50%
Conditioning
50%
Allogeneic Hematopoietic Stem Cell Transplantation
50%
Overall Survival
50%
Human Leukocyte Antigen
50%
Hypogammaglobulinemia
50%
Hematopoietic Cell
50%
Autoimmune Hemolytic Anemia
50%
Medicine and Dentistry
Pediatrics Patient
100%
Therapy Effect
100%
Late Effect
100%
Hematopoietic Stem Cell Transplantation
100%
Cytopenia
100%
Rituximab
25%
Stem Cell
12%
Transplantation
12%
B Cell
12%
Pediatrics
12%
Infection
12%
Immunoglobulin
12%
Engraftment
12%
Hematopoietic Cell
12%
Cell Transplantation
12%
Prophylaxis
12%
Chronic Graft Versus Host Disease
12%
Evans Syndrome
12%
Conditioning
12%
Overall Survival
12%
Human Leukocyte Antigen
12%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Avascular Necrosis
12%
Hypogammaglobulinemia
12%
Iron Overload
12%
Aplasia
12%
Case-Control Study
12%
Treatment Effect
12%
Daratumumab
12%
Graft Versus Host Reaction
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cytopenia
100%
Rituximab
25%
Graft Versus Host Reaction
12%
Case-Control Study
12%
Iron Poisoning
12%
Infection
12%
Immunoglobulin
12%
Chronic Graft Versus Host Disease
12%
Leukocyte Antigen
12%
Autoimmune Hemolytic Anemia
12%
Daratumumab
12%
Overall Survival
12%
Avascular Necrosis
12%
Immunoglobulin Deficiency
12%
Aplasia
12%